Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Myriad GeneticsHeskaRiot BlockchainLantheusCelldex Therapeutics
SymbolNASDAQ:MYGNNASDAQ:HSKANASDAQ:RIOTNASDAQ:LNTHNASDAQ:CLDX
Price Information
Current Price$28.80$180.48$48.40$21.33$23.71
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.01.41.31.71.8
Analysis Score0.92.53.52.43.5
Community Score1.92.42.62.53.1
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.01.71.7
Earnings & Valuation Score0.60.60.61.90.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$21.00$217.50$64.00$23.67$35.50
% Upside from Price Target-27.08% downside20.51% upside32.23% upside10.95% upside49.73% upside
Trade Information
Market Cap$2.10 billion$1.85 billion$4.22 billion$1.43 billion$882.23 million
Beta1.711.654.561.322.96
Average Volume813,10186,34430,197,213557,304706,857
Sales & Book Value
Annual Revenue$638.60 million$122.66 million$6.84 million$347.34 million$3.57 million
Price / Sales3.3915.32595.244.12263.10
Cashflow$0.71 per share$1.08 per shareN/A$2.12 per shareN/A
Price / Cash40.32166.71N/A10.04N/A
Book Value$12.32 per share$19.72 per share$1.06 per share$2.92 per share$5.83 per share
Price / Book2.349.1545.667.304.07
Profitability
Net Income$-199,500,000.00$-1,470,000.00$-20,040,000.00$31.67 million$-50,880,000.00
EPS($0.35)$0.05($0.73)$1.17($3.28)
Trailing P/E RatioN/AN/AN/A266.66N/A
Forward P/E RatioN/AN/A2,420.0043.53N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-32.49%-11.15%-250.06%0.12%-1,069.42%
Return on Equity (ROE)-4.07%-2.29%-51.38%11.05%-30.93%
Return on Assets (ROA)-2.68%-1.64%-47.50%5.43%-26.55%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.25%0.18%N/A0.40%N/A
Current Ratio2.95%4.96%32.21%2.25%16.63%
Quick Ratio2.75%3.79%32.21%1.79%16.63%
Ownership Information
Institutional Ownership Percentage96.72%96.11%9.01%84.95%80.15%
Insider Ownership Percentage2.80%11.70%3.50%2.08%2.40%
Miscellaneous
Employees2,7006026595123
Shares Outstanding75.21 million10.42 million84.12 million67.03 million39.62 million
Next Earnings Date5/4/2021 (Estimated)5/6/2021 (Confirmed)5/10/2021 (Estimated)4/29/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Celldex Therapeutics (NASDAQ:CLDX) Is In A Strong Position To Grow Its BusinessCelldex Therapeutics (NASDAQ:CLDX) Is In A Strong Position To Grow Its Business
nasdaq.com - April 13 at 12:00 AM
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
finance.yahoo.com - April 12 at 6:52 PM
Could Celldex Be a Millionaire-Maker Stock?Could Celldex Be a Millionaire-Maker Stock?
finance.yahoo.com - April 10 at 9:38 AM
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down to $21.00Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down to $21.00
americanbankingnews.com - April 9 at 11:42 AM
Celldex Therapeutics (NASDAQ:CLDX) Trading 3.7% Higher Celldex Therapeutics (NASDAQ:CLDX) Trading 3.7% Higher
americanbankingnews.com - April 7 at 2:38 PM
Celldex Therapeutics (NASDAQ:CLDX)  Shares Down 5% Celldex Therapeutics (NASDAQ:CLDX) Shares Down 5%
americanbankingnews.com - April 6 at 2:30 PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expected to Post Earnings of -$0.37 Per ShareCelldex Therapeutics, Inc. (NASDAQ:CLDX) Expected to Post Earnings of -$0.37 Per Share
americanbankingnews.com - April 2 at 2:12 AM
FY2021 EPS Estimates for Celldex Therapeutics, Inc. Increased by Cantor Fitzgerald (NASDAQ:CLDX)FY2021 EPS Estimates for Celldex Therapeutics, Inc. Increased by Cantor Fitzgerald (NASDAQ:CLDX)
americanbankingnews.com - April 1 at 8:36 AM
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 6.7%Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 6.7%
americanbankingnews.com - March 31 at 12:00 PM
Celldex Therapeutics Stock Appears To Be Significantly OvervaluedCelldex Therapeutics Stock Appears To Be Significantly Overvalued
finance.yahoo.com - March 31 at 1:56 AM
Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of ...Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of ...
apnews.com - March 30 at 10:41 AM
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down  Following Weak EarningsCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Down Following Weak Earnings
americanbankingnews.com - March 30 at 10:40 AM
Celldex Therapeutics (NASDAQ:CLDX) Issues Quarterly  Earnings ResultsCelldex Therapeutics (NASDAQ:CLDX) Issues Quarterly Earnings Results
americanbankingnews.com - March 30 at 7:24 AM
Celldex: Q4 Earnings SnapshotCelldex: Q4 Earnings Snapshot
myplainview.com - March 29 at 8:04 PM
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 ResultsCelldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results
finance.yahoo.com - March 29 at 8:04 PM
Why Is It Moving? Looking Into Why Celldex Therapeuticss Stock is Trading Lower TodayWhy Is It Moving? Looking Into Why Celldex Therapeutics's Stock is Trading Lower Today
msn.com - March 29 at 3:04 PM
Why Celldex Therapeutics Stock Is Tanking TodayWhy Celldex Therapeutics Stock Is Tanking Today
finance.yahoo.com - March 29 at 3:04 PM
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeCelldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume
americanbankingnews.com - March 29 at 12:51 PM
Celldexs CDX-0159 Shows 80% Response Rate In Early-Stage Skin Allergy StudyCelldex's CDX-0159 Shows 80% Response Rate In Early-Stage Skin Allergy Study
markets.businessinsider.com - March 29 at 10:03 AM
Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible UrticariaCelldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria
finance.yahoo.com - March 29 at 10:03 AM
Nasdaq Today – Acadia’s Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened WeekNasdaq Today – Acadia’s Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
fintechzoom.com - March 28 at 9:19 AM
Celldex Therapeutics (NASDAQ:CLDX)  Shares Down 6.4% Celldex Therapeutics (NASDAQ:CLDX) Shares Down 6.4%
americanbankingnews.com - March 26 at 1:50 PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s Analysis Might Be Just What You’re Looking ForCelldex Therapeutics, Inc. (NASDAQ:CLDX)’s Analysis Might Be Just What You’re Looking For
stocksregister.com - March 26 at 9:53 AM
First Week of April 16th Options Trading For Celldex Therapeutics (CLDX)First Week of April 16th Options Trading For Celldex Therapeutics (CLDX)
nasdaq.com - March 23 at 3:48 PM
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up to $25.09Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up to $25.09
americanbankingnews.com - March 22 at 11:30 AM
DateCompanyBrokerageAction
3/2/2021Myriad GeneticsSVB LeerinkBoost Price Target
11/10/2020Myriad GeneticsPiper SandlerBoost Price Target
8/14/2020Myriad GeneticsNeedham & Company LLCReiterated Rating
5/6/2020Myriad GeneticsJPMorgan Chase & Co.Lower Price Target
4/2/2020Myriad GeneticsBank of AmericaLower Price Target
3/26/2020Myriad GeneticsBarclaysLower Price Target
11/5/2019Myriad GeneticsPiper Jaffray CompaniesLower Price Target
8/14/2019Myriad GeneticsDeutsche Bank AktiengesellschaftLower Price Target
3/3/2021HeskaRaymond JamesBoost Price Target
2/24/2021HeskaAlliance Global PartnersReiterated Rating
3/27/2020HeskaSidotiLower Price Target
11/6/2019HeskaCanaccord GenuityReiterated Rating
5/23/2019HeskaGuggenheimInitiated Coverage
2/27/2019HeskaB. RileyLower Price Target
4/1/2021Riot BlockchainHC WainwrightBoost Price Target
3/4/2021LantheusCredit Suisse GroupBoost Price Target
6/29/2020LantheusJefferies Financial GroupInitiated Coverage
6/16/2020LantheusCJS SecuritiesUpgrade
8/2/2018LantheusWells Fargo & CompanyLower Price Target
2/23/2021Celldex TherapeuticsCantor FitzgeraldBoost Price Target
11/17/2020Celldex TherapeuticsLifesci CapitalReiterated Rating
8/9/2018Celldex TherapeuticsCowenReiterated Rating
(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.